- -

Profile of the Roche cobas (R) EGFR mutation test for non-small cell lung cancer

RiuNet: Institutional repository of the Polithecnic University of Valencia

Share/Send to

Cited by

Statistics

Profile of the Roche cobas (R) EGFR mutation test for non-small cell lung cancer

Show full item record

Malapelle, U.; Sirera Pérez, R.; Jantus-Lewintre, E.; Reclusa, P.; Calabuig-Farinas, S.; Blasco, A.; Pisapia, P.... (2017). Profile of the Roche cobas (R) EGFR mutation test for non-small cell lung cancer. Expert Review of Molecular Diagnostics. 17(3):209-215. https://doi.org/10.1080/14737159.2017.1288568

Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10251/147918

Files in this item

Item Metadata

Title: Profile of the Roche cobas (R) EGFR mutation test for non-small cell lung cancer
Author: Malapelle, Umberto Sirera Pérez, Rafael Jantus-Lewintre, Eloisa Reclusa, P. Calabuig-Farinas, S. Blasco, Ana Pisapia, P. Rolfo, C. Camps, Carlos
UPV Unit: Universitat Politècnica de València. Departamento de Biotecnología - Departament de Biotecnologia
Issued date:
Abstract:
[EN] Introduction: The discovery of driver mutations in non-small cell lung cancer (NSCLC) has led to the development of genome-based personalized medicine. Fifteen to 20% of adenocarcinomas harbor an epidermal growth ...[+]
Subjects: EGFR , Cobas (R) , Liquid biopsy , Companion diagnostic , Mutation , Resistance , TKIs
Copyrigths: Cerrado
Source:
Expert Review of Molecular Diagnostics. (issn: 1473-7159 )
DOI: 10.1080/14737159.2017.1288568
Publisher:
Taylor & Francis
Publisher version: https://doi.org/10.1080/14737159.2017.1288568
Project ID:
info:eu-repo/grantAgreement/MINECO//CB16%2F12%2F00350/ES/CANCER/
Thanks:
This work was partially supported by FEDER, CIBERONC, grant number [CB16/12/00350].
Type: Artículo

References

Ridge, C., McErlean, A., & Ginsberg, M. (2013). Epidemiology of Lung Cancer. Seminars in Interventional Radiology, 30(02), 093-098. doi:10.1055/s-0033-1342949

Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., … Fukuoka, M. (2009). Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma. New England Journal of Medicine, 361(10), 947-957. doi:10.1056/nejmoa0810699

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., … Haber, D. A. (2004). Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib. New England Journal of Medicine, 350(21), 2129-2139. doi:10.1056/nejmoa040938 [+]
Ridge, C., McErlean, A., & Ginsberg, M. (2013). Epidemiology of Lung Cancer. Seminars in Interventional Radiology, 30(02), 093-098. doi:10.1055/s-0033-1342949

Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., … Fukuoka, M. (2009). Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma. New England Journal of Medicine, 361(10), 947-957. doi:10.1056/nejmoa0810699

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., … Haber, D. A. (2004). Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib. New England Journal of Medicine, 350(21), 2129-2139. doi:10.1056/nejmoa040938

Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., … Sanchez, J. M. (2012). Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. The Lancet Oncology, 13(3), 239-246. doi:10.1016/s1470-2045(11)70393-x

Yang, J. C.-H., Wu, Y.-L., Schuler, M., Sebastian, M., Popat, S., Yamamoto, N., … Sequist, L. V. (2015). Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. The Lancet Oncology, 16(2), 141-151. doi:10.1016/s1470-2045(14)71173-8

Jänne, P. A., Yang, J. C.-H., Kim, D.-W., Planchard, D., Ohe, Y., Ramalingam, S. S., … Ranson, M. (2015). AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer. New England Journal of Medicine, 372(18), 1689-1699. doi:10.1056/nejmoa1411817

Pirker, R., Herth, F. J. F., Kerr, K. M., Filipits, M., Taron, M., Gandara, D., … Stahel, R. (2010). Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop. Journal of Thoracic Oncology, 5(10), 1706-1713. doi:10.1097/jto.0b013e3181f1c8de

Malapelle, U., Russo, S., Pepe, F., Sgariglia, R., De Luca, C., Bellevicine, C., … Troncone, G. (2013). EGFR mutation detection by microfluidic technology: a validation study. Journal of Clinical Pathology, 66(11), 982-984. doi:10.1136/jclinpath-2013-201730

Malapelle, U., Bellevicine, C., De Luca, C., Salatiello, M., De Stefano, A., Rocco, D., … Troncone, G. (2013). EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung carcinoma patients. Cancer Cytopathology, 121(10), 552-560. doi:10.1002/cncy.21322

Giannini, R., Lupi, C., Sensi, E., Alì, G., Proietti, A., Boldrini, L., … Fontanini, G. (2016). EGFR and KRAS mutational analysis in a large series of Italian non-small cell lung cancer patients: 2,387 cases from a single center. Oncology Reports, 36(2), 1166-1172. doi:10.3892/or.2016.4874

De Biase, D., Visani, M., Malapelle, U., Simonato, F., Cesari, V., Bellevicine, C., … Tallini, G. (2013). Next-Generation Sequencing of Lung Cancer EGFR Exons 18-21 Allows Effective Molecular Diagnosis of Small Routine Samples (Cytology and Biopsy). PLoS ONE, 8(12), e83607. doi:10.1371/journal.pone.0083607

Lozano, M. D., Labiano, T., Echeveste, J., Gurpide, A., Martín‐Algarra, S., Zhang, G., … Palma, J. F. (2014). Assessment of EGFR and KRAS mutation status from FNAs and core‐needle biopsies of non‐small cell lung cancer. Cancer Cytopathology, 123(4), 230-236. doi:10.1002/cncy.21513

Hantson, I., Dooms, C., Verbeken, E., Vandenberghe, P., Vliegen, L., Roskams, T., … Vansteenkiste, J. (2014). Performance of standard procedures in detection of EGFR mutations in daily practice in advanced NSCLC patients selected according to the ESMO guideline: a large Caucasian cohort study. Translational Respiratory Medicine, 2(1). doi:10.1186/s40247-014-0009-0

Crowley, E., Di Nicolantonio, F., Loupakis, F., & Bardelli, A. (2013). Liquid biopsy: monitoring cancer-genetics in the blood. Nature Reviews Clinical Oncology, 10(8), 472-484. doi:10.1038/nrclinonc.2013.110

Schwarzenbach, H., Hoon, D. S. B., & Pantel, K. (2011). Cell-free nucleic acids as biomarkers in cancer patients. Nature Reviews Cancer, 11(6), 426-437. doi:10.1038/nrc3066

Sundaresan, T. K., Sequist, L. V., Heymach, J. V., Riely, G. J., Ja nne, P. A., Koch, W. H., … Haber, D. A. (2015). Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses. Clinical Cancer Research, 22(5), 1103-1110. doi:10.1158/1078-0432.ccr-15-1031

Chia, P. L., Do, H., Morey, A., Mitchell, P., Dobrovic, A., & John, T. (2016). Temporal changes of EGFR mutations and T790M levels in tumour and plasma DNA following AZD9291 treatment. Lung Cancer, 98, 29-32. doi:10.1016/j.lungcan.2016.05.003

Alix-Panabières, C., & Pantel, K. (2013). Circulating Tumor Cells: Liquid Biopsy of Cancer. Clinical Chemistry, 59(1), 110-118. doi:10.1373/clinchem.2012.194258

Yao, Y., Liu, J., Li, L., Yuan, Y., Nan, K., Wu, X., … Jiang, Z. (2016). Detection of circulating tumor DNA in patients with advanced non-small cell lung cancer. Oncotarget, 8(2), 2130-2140. doi:10.18632/oncotarget.12883

Camps, C., Jantus-Lewintre, E., Cabrera, A., Blasco, A., Sanmartín, E., Gallach, S., … Sirera, R. (2011). The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients. Lung Cancer, 72(3), 365-369. doi:10.1016/j.lungcan.2010.09.005

Dawson, S.-J., Tsui, D. W. Y., Murtaza, M., Biggs, H., Rueda, O. M., Chin, S.-F., … Rosenfeld, N. (2013). Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer. New England Journal of Medicine, 368(13), 1199-1209. doi:10.1056/nejmoa1213261

Ankeny, J. S., Court, C. M., Hou, S., Li, Q., Song, M., Wu, D., … Tomlinson, J. S. (2016). Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer. British Journal of Cancer, 114(12), 1367-1375. doi:10.1038/bjc.2016.121

Tan, C. R. C., Zhou, L., & El-Deiry, W. S. (2016). Circulating Tumor Cells Versus Circulating Tumor DNA in Colorectal Cancer: Pros and Cons. Current Colorectal Cancer Reports, 12(3), 151-161. doi:10.1007/s11888-016-0320-y

Malapelle, U., Pisapia, P., Rocco, D., Smeraglio, R., di Spirito, M., Bellevicine, C., & Troncone, G. (2016). Next generation sequencing techniques in liquid biopsy: focus on non-small cell lung cancer patients. Translational Lung Cancer Research, 5(5), 505-510. doi:10.21037/tlcr.2016.10.08

Sirera, R., Bremnes, R. M., Cabrera, A., Jantus-Lewintre, E., Sanmartín, E., Blasco, A., … Camps, C. (2011). Circulating DNA is a Useful Prognostic Factor in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 6(2), 286-290. doi:10.1097/jto.0b013e31820189a5

Lianidou, E. S., Mavroudis, D., & Georgoulias, V. (2013). Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer. British Journal of Cancer, 108(12), 2426-2432. doi:10.1038/bjc.2013.265

Diamandis, E. P., Pantel, K., Scher, H. I., Terstappen, L., & Lianidou, E. (2011). Circulating Cancer Cells and Their Clinical Applications. Clinical Chemistry, 57(11), 1478-1484. doi:10.1373/clinchem.2011.166678

Karachaliou, N., Mayo-de las Casas, C., Queralt, C., de Aguirre, I., Melloni, B., Cardenal, F., … Rosell, R. (2015). Association ofEGFRL858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial. JAMA Oncology, 1(2), 149. doi:10.1001/jamaoncol.2014.257

Pasquale, R., Fenizia, F., Esposito Abate, R., Sacco, A., Esposito, C., Forgione, L., … Normanno, N. (2015). Assessment of high-sensitive methods for the detection of EGFR mutations in circulating free tumor DNA from NSCLC patients. Pharmacogenomics, 16(10), 1135-1148. doi:10.2217/pgs.15.45

Thress, K. S., Brant, R., Carr, T. H., Dearden, S., Jenkins, S., Brown, H., … Barrett, J. C. (2015). EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291. Lung Cancer, 90(3), 509-515. doi:10.1016/j.lungcan.2015.10.004

Kimura, H., Ohira, T., Uchida, O., Matsubayashi, J., Shimizu, S., Nagao, T., … Nishio, K. (2014). Analytical performance of the cobas EGFR mutation assay for Japanese non-small-cell lung cancer. Lung Cancer, 83(3), 329-333. doi:10.1016/j.lungcan.2013.12.012

Benlloch, S., Botero, M. L., Beltran-Alamillo, J., Mayo, C., Gimenez-Capitán, A., de Aguirre, I., … Taron, M. (2014). Clinical Validation of a PCR Assay for the Detection of EGFR Mutations in Non–Small-Cell Lung Cancer: Retrospective Testing of Specimens from the EURTAC Trial. PLoS ONE, 9(2), e89518. doi:10.1371/journal.pone.0089518

Wu, Y.-L., Zhou, C., Liam, C.-K., Wu, G., Liu, X., Zhong, Z., … Zuo, Y. (2015). First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Annals of Oncology, 26(9), 1883-1889. doi:10.1093/annonc/mdv270

Beau-Faller, M., Prim, N., Ruppert, A.-M., Nanni-Metéllus, I., Lacave, R., Lacroix, L., … Cadranel, J. (2014). Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network. Annals of Oncology, 25(1), 126-131. doi:10.1093/annonc/mdt418

Yasuda, H., Kobayashi, S., & Costa, D. B. (2012). EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. The Lancet Oncology, 13(1), e23-e31. doi:10.1016/s1470-2045(11)70129-2

Oxnard, G. R., Thress, K. S., Alden, R. S., Lawrance, R., Paweletz, C. P., Cantarini, M., … Jänne, P. A. (2016). Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 34(28), 3375-3382. doi:10.1200/jco.2016.66.7162

Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., … Halmos, B. (2005). EGFRMutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib. New England Journal of Medicine, 352(8), 786-792. doi:10.1056/nejmoa044238

Balak, M. N., Gong, Y., Riely, G. J., Somwar, R., Li, A. R., Zakowski, M. F., … Pao, W. (2006). Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor-Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors. Clinical Cancer Research, 12(21), 6494-6501. doi:10.1158/1078-0432.ccr-06-1570

Costa, D. B., Schumer, S. T., Tenen, D. G., & Kobayashi, S. (2008). Differential Responses to Erlotinib in Epidermal Growth Factor Receptor (EGFR)-Mutated Lung Cancers With Acquired Resistance to Gefitinib Carrying the L747S or T790M Secondary Mutations. Journal of Clinical Oncology, 26(7), 1182-1184. doi:10.1200/jco.2007.14.9039

Thress, K. S., Paweletz, C. P., Felip, E., Cho, B. C., Stetson, D., Dougherty, B., … Oxnard, G. R. (2015). Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M. Nature Medicine, 21(6), 560-562. doi:10.1038/nm.3854

Bean, J., Riely, G. J., Balak, M., Marks, J. L., Ladanyi, M., Miller, V. A., & Pao, W. (2008). Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with EGFR-Mutant Lung Adenocarcinoma. Clinical Cancer Research, 14(22), 7519-7525. doi:10.1158/1078-0432.ccr-08-0151

Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., … Janne, P. A. (2007). MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling. Science, 316(5827), 1039-1043. doi:10.1126/science.1141478

[-]

recommendations

 

This item appears in the following Collection(s)

Show full item record